BOSTON, Sept. 30 /PRNewswire-FirstCall/ -- Solos Endoscopy, Inc. (Pink Sheets: SNDY) is pleased to announce that the Company intends to expand their current industry to include and capitalize on the $30 billion minimally invasive instrumentation market by implementing a business strategy. The Company's strategy is expected to substantially increase its revenue, and simultaneously increase its customer base.
Solos Endoscopy expects continuous growth in this market because physicians are developing new minimally invasive techniques, not only in the traditional area of general surgery, but also in other medical specialty areas. This shift in the Company's business strategy will allow many more procedures to be performed outside the operating room setting and this expansion creates an increased demand for high quality instrumentation in the medical product market.
"Our initiative for 2008 is to enhance the instrumentation that we have developed in the general surgery line, and to move our surgical instrument division into diverse specialties. We believe that we have a great future; our reputation in the medical industry is that we build excellent instruments and this, coupled with our new products, will significantly expand our revenue and customer base in the future," stated Robert Segersten, President of Solos Endoscopy, Inc.
For additional information on Solos Endoscopy, Inc. please visit http://www.solosendoscopy.com .
About Solos Endoscopy, Inc.
Solos Endoscopy, Inc. is a healthcare technology company whose mission is to develop and market breakthrough technology, applications, medical devices, and procedural techniques for the screening, diagnosis, treatment and management of disease and medical conditions. Backed by technical support, Solos' sales team can help make the right buying decisions for the hospital, surgery center, or physician office. Additional information is available on the Company's website at: http://www.solosendoscopy.com .
Safe Harbor: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions.
|SOURCE Solos Endoscopy, Inc.|
Copyright©2008 PR Newswire.
All rights reserved